Skip to content

US · SPRC · BIOTECHNOLOGY

SciSparc Ltd. (SPRC) intrinsic value and stock valuation

$0.20as of 2026-11-21 · Mkt cap 398.51K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SciSparc Ltd. DCF and intrinsic value

InvestorsCraft values SPRC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SPRC’s statements →

SciSparc Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Tel Aviv, TA 6971916 scisparc.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$860K+9.4% 5y CAGRd
20112025
Net income
-$-12.18M
20112025
Free cash flow
-$-4.14M
20112025
Total equity
$5.15M+29.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$860K$1.31M$2.88M$1.35M$1.07M
Operating income-$-8.75M-$-7.32M-$-5.77M-$-7.38M-$-5.77M
Net income-$-12.18M-$-6.28M-$-5.12M-$-2.59M-$-5.8M
EPSd-$-882.61K-$-9.66M-$-22.26M-$-25.9M-$-64.44M
Operating cash flow-$-4.14M-$-5.1M-$-5.89M-$-7.92M-$-5.06M
Capital expenditure$0.00$0.00$0.00-$-4.87M-$-40K
Free cash flow-$-4.14M-$-5.1M-$-5.89M-$-12.79M-$-5.1M
Total assets$7.62M$10.4M$11.2M$10.6M$9.92M
Total debt$370K$50K$80K$30K$500K
Net debt-$-4.22M-$-1.49M-$-2M-$-3.55M-$-6.37M
Total equity$5.15M$8.94M$9.59M$6.45M$8.14M
Cash and short-term investments$4.59M$2.06M$5.08M$3.57M$6.88M
Income statement
20252024202320222021
Revenue$860K$1.31M$2.88M$1.35M$1.07M
Cost of revenue$230K$800K$680K$320K$30K
Gross profit$630K$510K$2.2M$1.02M$1.04M
Research and development expenses$2.19M$1.81M$1.64M$2.8M$1.99M
Selling, general and administrative expenses$5.44M$5.8M$6.13M$6.27M$3.64M
Other expenses$1.76M$200K$0.00$220K$140K
Operating expenses$9.38M$7.82M$7.97M$8.4M$5.77M
Cost and expenses$9.61M$8.62M$8.65M$8.73M$5.77M
Interest income$210K$420K$0.00$1.24M$20K
Interest expense$10K$30K$10K$40K$10K
Depreciation and amortization$230K$480K$540K$190K$30K
Ebitda-$-12.32M-$-6.97M-$-5.31M-$-2.35M-$-5.74M
Operating income-$-8.75M-$-7.32M-$-5.77M-$-7.38M-$-5.77M
Total other income/expenses, net-$-3.81M-$-170K-$-90K$4.8M-$-20K
Income before tax-$-12.56M-$-7.49M-$-5.86M-$-2.58M-$-5.79M
Income tax expense$0.00-$-10K$20K$10K$0.00
Net income-$-12.18M-$-6.28M-$-5.12M-$-2.59M-$-5.8M
Weighted average shares outstanding$13.8M$650K$200K$100K$90K
Weighted average diluted shares outstanding$13.8M$650K$230K$100K$90K
Balance sheet
20252024202320222021
Cash and short-term investments$4.59M$2.06M$5.08M$3.57M$6.88M
Net receivables$660K$4.96M$290K$170K$2.56M
Inventory$70K$110K$740K$670K$40K
Total current assets$5.44M$7.5M$6.45M$4.51M$9.82M
Property, plant and equipment, net$20K$60K$110K$60K$90K
Goodwill and intangible assets$1.17M$1.48M$3.19M$4.72M$0.00
Long-term investments$1M$1.31M$1.44M$1.32M$0.00
Total non-current assets$2.19M$2.84M$4.74M$6.09M$90K
Total assets$7.62M$10.4M$11.2M$10.6M$9.92M
Accounts payable$780K$820K$260K$300K$440K
Short-term debt$370K$40K$50K$30K$490K
Deferred revenue$0.00$0.00$0.00$0.00-$-150K
Total current liabilities$2.25M$1.4M$1.57M$4.16M$1.76M
Long-term debt$0.00$10K$20K$0.00$20K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$220K$10K$20K$1.23M$20K
Capital lease obligations$10K$50K$80K$30K$60K
Total liabilities$2.48M$1.41M$1.59M$4.16M$1.77M
Common stock$76.5M$70.9M$64.5M$58.6M$58.5M
Retained earnings-$-87.15M-$-74.97M-$-68.69M-$-63.57M-$-60.98M
Accumulated other comprehensive income (loss)$1.91M$500K$11.8M$11.4M$10.6M
Total equity$5.15M$8.94M$9.59M$6.45M$8.14M
Total investments$1M$1.82M$4.44M$1.32M$0.00
Total debt$370K$50K$80K$30K$500K
Net debt-$-4.22M-$-1.49M-$-2M-$-3.55M-$-6.37M
Cash flow statement
20252024202320222021
Net income-$-12.56M-$-7.47M-$-5.12M-$-2.59M-$-5.79M
Depreciation and amortization$230K$480K$540K$190K$30K
Stock-based compensation$1.19M$570K$200K$900K$40K
Change in working capital$1.45M$140K-$-830K-$-700K$640K
Accounts receivable$790K-$-520K-$-350K-$-80K$170K
Inventory$40K$630K-$-70K-$-670K-$-170K
Accounts payable-$-160K$30K-$-400K$0.00$350K
Net cash provided by operating activities-$-4.14M-$-5.1M-$-5.89M-$-7.92M-$-5.06M
Investments in property, plant and equipment$0.00$0.00$0.00-$-4.87M-$-40K
Acquisitions, net$600K-$-600K$2.58M-$-700K$0.00
Net cash used for investing activities-$-1.4M-$-1.62M-$-1.11M-$-7.08M-$-70K
Common stock issued$4.09M$6.25M$5.55M$9.01M$7.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.59M$6.19M$5.5M$11.7M$10.1M
Net change in cash$3.05M-$-540K-$-1.5M-$-3.3M$4.93M
Cash at end of period$4.59M$1.54M$2.08M$3.57M$6.88M
Operating cash flow-$-4.14M-$-5.1M-$-5.89M-$-7.92M-$-5.06M
Capital expenditure$0.00$0.00$0.00-$-4.87M-$-40K
Free cash flow-$-4.14M-$-5.1M-$-5.89M-$-12.79M-$-5.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SciSparc Ltd.

        SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.

        CEO
        Oz Adler
        Employees
        3
        Beta
        2.48

        Explore

        Frequently asked questions

        What is the intrinsic value of SciSparc Ltd. (SPRC)?

        InvestorsCraft does not currently publish an intrinsic value for SPRC. How the IC value is calculated.

        Is SPRC undervalued?

        InvestorsCraft does not publish an undervaluation signal for SPRC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.